PineStone Asset Management Inc. decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 37.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 837,126 shares of the medical instruments supplier’s stock after selling 508,747 shares during the period. Becton, Dickinson and Company makes up approximately 1.9% of PineStone Asset Management Inc.’s investment portfolio, making the stock its 21st largest holding. PineStone Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $201,831,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of the business. Nordea Investment Management AB boosted its position in shares of Becton, Dickinson and Company by 277.3% during the 1st quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock worth $478,295,000 after purchasing an additional 1,423,353 shares in the last quarter. M&G Plc purchased a new stake in Becton, Dickinson and Company during the first quarter worth about $173,692,000. First Eagle Investment Management LLC grew its position in Becton, Dickinson and Company by 32.5% during the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after buying an additional 688,296 shares during the period. Bank of New York Mellon Corp increased its holdings in Becton, Dickinson and Company by 8.5% in the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after buying an additional 346,720 shares in the last quarter. Finally, Magnetar Financial LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at approximately $75,493,000. 86.97% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
BDX has been the subject of several research reports. Raymond James reduced their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Stifel Nicolaus lifted their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Evercore ISI raised their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $282.63.
Becton, Dickinson and Company Stock Down 1.3 %
Shares of NYSE:BDX opened at $233.49 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The firm has a market cap of $67.49 billion, a price-to-earnings ratio of 48.04, a PEG ratio of 1.79 and a beta of 0.42. The stock’s 50-day moving average price is $237.58 and its two-hundred day moving average price is $235.04. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $259.92.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same period in the previous year, the company earned $2.96 EPS. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, research analysts forecast that Becton, Dickinson and Company will post 13.11 EPS for the current year.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Top 3 REIT Picks for 2025: High Yields and Rising Earnings Ahead
- What Makes a Stock a Good Dividend Stock?
- 3 Stocks Well Below 52-Week Highs With Strong Growth Projections
- Differences Between Momentum Investing and Long Term Investing
- 3 Chip Stocks Expected to See Accelerating Sales Growth
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.